| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 0 | 13.658 | 32.689 | 45.111 | 47.147 |
| Total Income - EUR | - | - | - | - | - | 6.308 | 51.895 | 39.402 | 52.673 | 50.074 |
| Total Expenses - EUR | - | - | - | - | - | 6.280 | 61.124 | 53.724 | 51.871 | 43.567 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 28 | -9.228 | -14.322 | 802 | 6.507 |
| Net Profit/Loss - EUR | - | - | - | - | - | 28 | -9.228 | -14.522 | 324 | 5.076 |
| Employees | - | - | - | - | - | 2 | 3 | 3 | 3 | 2 |
Check the financial reports for the company - Relivemed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 2.714 | 24.309 | 18.737 | 13.023 | 11.661 |
| Current Assets | - | - | - | - | - | 73.016 | 12.234 | 7.987 | 8.838 | 12.564 |
| Inventories | - | - | - | - | - | 6.072 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | 65.949 | 1.793 | 2.258 | 4.333 | 410 |
| Cash | - | - | - | - | - | 995 | 10.441 | 5.728 | 4.505 | 12.154 |
| Shareholders Funds | - | - | - | - | - | 69 | -9.160 | -23.711 | -23.315 | -18.108 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 15.974 | 22.577 | 33.802 | 33.573 | 33.244 |
| Income in Advance | - | - | - | - | - | 59.687 | 23.248 | 16.635 | 11.694 | 9.241 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Relivemed S.r.l.